Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.H Lundbeck has initiated a Phase III clinical trial to evaluate Zicronapine and expects to recruit around 160 schizophrenia patients.
Subscribe to our email newsletter
The study aims to measure the efficacy of Zicronapine and risperidone and their relative impact on key metabolic parameters.
In the trial, the patients will be randomly assigned to Zicronapine (7.5mg/day) or risperidone (5mg/day) treatment in a 1:1 ratio.
Lundbeck Development head and executive vice president Anders Gersel Pedersen said with Zicronapine, they look forward to be able to offer patients and their physicians a new treatment option within an area still characterized by substantial unmet medical needs.